As seen, Venetoclax is showing itself to be a very promising therapeutic, against Bcl-2-dependent cancer cells such as CLL, acute leukemias, breast cancer, myc-driven lymphomas [293–295], and through successful phase I-III trials for acute myeloid leukemia (AML), CLL, MM and non-Hodgkin’s lymphoma (NHL) [296], it was ultimately awarded US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) approval for treating CLL patients harboring the 17p or p53 mutations [445]. This evidence concerns the gene MYC and acute myeloid leukemia.